Literature DB >> 9536483

Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction.

J D Port1, N J Beauchamp.   

Abstract

Several cerebral pathologic processes thought to result from derangements in vascular autoregulatory mechanisms show reversible abnormalities on computed tomographic and magnetic resonance images. The hypertensive encephalopathies are characterized by intracranial abnormalities due to subacutely elevated blood pressure; these entities include hypertensive encephalopathy, preeclampsia and eclampsia, and cyclosporine toxicity. Imaging studies reveal symmetric confluent lesions with mild mass effect and patchy enhancement centered in the immediate subcortical white matter of the occipital lobes. The uremic encephalopathies are characterized by intracranial abnormalities due to an elevated level of blood urea nitrogen; these entities include uremia and glomerulonephritis, hemolytic-uremic syndrome, and thrombotic thrombocytopenic purpura. Imaging studies reveal multiple areas of symmetric edema in the basal ganglia; in severe cases, focal infarcts with or without hemorrhage can be seen. As radiologists become more familiar with these entities, cases can be recognized earlier in the disease process, allowing more timely initiation of appropriate therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9536483     DOI: 10.1148/radiographics.18.2.9536483

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  31 in total

1.  Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome.

Authors:  Florian S Eichler; Paul Wang; Robert J Wityk; Norman J Beauchamp; Peter B Barker
Journal:  AJNR Am J Neuroradiol       Date:  2002-05       Impact factor: 3.825

2.  Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions.

Authors:  S O Casey; R C Sampaio; E Michel; C L Truwit
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

3.  The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke.

Authors:  John S Smeda; Noriko Daneshtalab
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-21       Impact factor: 6.200

4.  Placental ischemia impairs middle cerebral artery myogenic responses in the pregnant rat.

Authors:  Michael J Ryan; Emily L Gilbert; Porter H Glover; Eric M George; C Warren Masterson; Gerald R McLemore; Babbette LaMarca; Joey P Granger; Heather A Drummond
Journal:  Hypertension       Date:  2011-11-07       Impact factor: 10.190

5.  [Von-Hippel-Lindau disease Type IIa with hypertensive crisis].

Authors:  F L Giesel; A Evans; C Zechmann; H von Tengg-Kobligk; P D Griffiths; M Essig
Journal:  Radiologe       Date:  2006-03       Impact factor: 0.635

6.  Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia.

Authors:  P S Rangi; W J Partridge; E S Newlands; A D Waldman
Journal:  Neuroradiology       Date:  2005-07-05       Impact factor: 2.804

7.  Posterior Reversible Encephalopathy Syndrome: Local Experience From Saudi Arabia.

Authors:  Hussein Algahtani; Abdulhadi Algahtani; Ahmad Aldarmahi; Mohammed Hmoud; Yousef Marzuk; Bader Shirah
Journal:  Neurohospitalist       Date:  2016-08-31

8.  Reply.

Authors:  I H Lee; D M Kim; C J Song
Journal:  AJNR Am J Neuroradiol       Date:  2017-01-12       Impact factor: 3.825

9.  Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?

Authors:  Christina Mueller-Mang; Thomas Mang; Agnes Pirker; Katharina Klein; Christine Prchla; Daniela Prayer
Journal:  Neuroradiology       Date:  2009-02-21       Impact factor: 2.804

10.  Hypertensive encephalopathy: isolated pons involvement mimicking central pontine myelinolysis.

Authors:  S Gamanagatti; S Subramanian
Journal:  Korean J Radiol       Date:  2006 Jul-Sep       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.